World Health Organization: Wormwood for Malaria

[Guest guest]

http://www.who.int/mediacentre/notes/np8/en/

the disease kills more than one million people every year, mostly children

under the age of five in Africa

http://www.who.int/tdr/publications/tdrnews/news63/artemotil.htm

Clinical studies in patients with severe malaria were carried out first in

adults and later in children who could not be treated with oral medication, or

who had critical cerebral malaria, in Africa and Thailand. No serious or

inconvenient side effects were reported. Although, with artemisinin compounds in

general, degenerative neurotoxic effects have been reported during pre-clinical

safety studies in animals, these have occured at cumulative doses above 100 mg

per kg body weight, whereas, in clinical treatment with artemotil, the

cumulative dose reached is 11.2 mg per kg. Also, throughout the world, during

treatment of millions of patients with various artemisinin derivatives, no

neurotoxic

effects have been reported. Nor has neurotoxicity been observed during

controlled studies in volunteers and patients. Thus there is no reason for

restriction of clinical use of artemotil.